Covidien (Booth 9113) is featuring its contrast delivery system with radio-frequency identification (RFID) technology. The system combines its unit-dose RFID-enabled Ultraject prefilled contrast media syringes with its RFID-enabled Optivantage DH power injector to provide the only contrast delivery solution of its type available in North America. RFID is an automatic identification technology that captures, stores and transmits data between the syringe and the power injector using devices called RFID transponders, or tags.  

The system creates an intelligent interface between the contrast media syringe and the power injector that helps technologists better ensure that each patient receives the prescribed concentration and programmed dose of a contrast media-related drug during a procedure. The interface allows the injector to physically alter the RFID label on a syringe once it is used, thus disabling its future use, which prevents an accidental air embolism caused from using an empty, used syringe. It also prevents accidental patient cross-contamination from using a partially used syringe in another patient exam. Covidien’s system also indicates if the drug, in an RFID-labeled syringe, is past its expiration date. Additionally, the system automatically transfers drug and achieved exam protocol information onto a printed label for the patient record, which reduces the need for manual data entry, thereby offering the potential to help increase efficiency and accuracy.  

The company also is showcasing the Optistar Elite contrast delivery system, designed to inject MR contrast media into a patient’s vascular system.